Last Updated: August 8, 2026

Details for Patent: 12,156,869


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,156,869 protect, and when does it expire?

Patent 12,156,869 protects ARBLI and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 12,156,869
Title:Losartan liquid formulations and methods of use
Abstract:The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
Inventor(s):Bhavya Teja KOLLA, Rahul Surana, Suketu Sanghvi, Jigar BHATT
Assignee: Meds Merger Sub Ii LLC , Scienture LLC
Application Number:US18/421,405
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

error: insufficient information

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,156,869

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Scienture ARBLI losartan potassium SUSPENSION;ORAL 218772-001 Mar 13, 2025 RX Yes Yes 12,156,869 ⤷  Start Trial Y A METHOD OF USING LOSARTAN FOR THE REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY ⤷  Start Trial
Scienture ARBLI losartan potassium SUSPENSION;ORAL 218772-001 Mar 13, 2025 RX Yes Yes 12,156,869 ⤷  Start Trial Y A METHOD OF USING LOSARTAN FOR THE TREATMENT OF HYPERTENSION ⤷  Start Trial
Scienture ARBLI losartan potassium SUSPENSION;ORAL 218772-001 Mar 13, 2025 RX Yes Yes 12,156,869 ⤷  Start Trial Y A METHOD OF USING LOSARTAN FOR THE TREATMENT OF DIABETIC NEPHROPATHY WITH AN ELEVATED SERUM CREATININE AND PROTEINURIA IN PATIENTS WITH TYPE 2 DIABETES AND A HISTORY OF HYPERTENSION ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,156,869

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2022076746 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.